Belzutifan-lenvatinib slows progression versus cabozantinib with much longer response dura ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

Arcus Biosciences (NYSE:RCUS) reported positive late stage efficacy results for casdatifan, its investigational HIF-2a inhibitor, in late line renal cell carcinoma. The company released biomarker ...

Earlier analyses demonstrated strong local tumor control, with nearly nine in 10 patients remaining free of recurrence at ...

The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, ...

SALT LAKE CITY — The five-year survival rate for all cancers combined has reached a historic 70%, according to the latest American Cancer Society Cancer Statistics 2026 report, based on all people ...